Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Statement of unaudited Standalone Financial Results for the quarter and half year ended 30 September 2026

(Rs. in Million, except per equity share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
1	**Income**						
	a) Revenue from operations	1,145.71	832.66	832.21	1,978.37	1,625.73	3,482.41
	b) Other income	220.82	231.45	242.25	452.27	505.13	1,137.23
	Total income	**1,366.53**	**1,064.11**	**1,074.46**	**2,430.64**	**2,130.86**	**4,619.64**
2	**Expenses**						
	a) Purchase of Stock-in-trade	791.37	568.13	612.96	1,359.50	1,572.09	2,780.65
	b) Changes in inventories of Stock-in-trade	(10.80)	161.05	94.80	150.25	(163.43)	356.41
	c) Employee benefits expense	161.08	122.94	143.28	284.02	283.06	578.72
	d) Finance costs	61.11	57.42	7.11	118.53	13.05	46.08
	e) Depreciation and amortisation expense	31.72	31.07	33.22	62.79	61.45	117.22
	f) Other expenses	88.86	77.45	106.99	166.31	196.90	393.73
	Total Expenses	**1,123.34**	**1,018.06**	**998.37**	**2,141.40**	**1,963.13**	**4,272.81**
3	**Profit before exceptional items and tax (1) - (2)**	**243.19**	**46.05**	**76.09**	**289.24**	**167.73**	**346.83**
4	**Exceptional items**	-	-	-	-	-	44.97
5	**Profit before tax (3) - (4)**	**243.19**	**46.05**	**76.09**	**289.24**	**167.73**	**301.86**
6	**Tax expenses**						
	Current tax (including tax expense of earlier year)	3.04	2.20	18.03	5.24	18.03	89.06
	Deferred tax charge/(credit)	48.71	9.28	1.10	57.99	23.17	(55.95)
	Total tax expenses	**51.75**	**11.48**	**19.13**	**63.23**	**41.20**	**33.11**
7	**Profit for the period/year (5) –(6)**	**191.44**	**34.57**	**56.96**	**226.01**	**126.53**	**268.75**
8	**Other comprehensive income**						
	Items that will not be reclassified subsequently to profit and loss						
	Remeasurement gain / (loss) on defined benefit plan	3.71	(0.94)	(1.12)	2.77	(0.73)	(3.75)
	Income tax effect on above	(0.94)	0.24	0.28	(0.70)	0.18	0.94
	Total other comprehensive income	**2.77**	**(0.70)**	**(0.84)**	**2.07**	**(0.55)**	**(2.81)**
9	**Total comprehensive income (7) + (8)**	**194.21**	**33.87**	**56.12**	**228.08**	**125.98**	**265.94**
10	Paid-up equity share capital (face value - Rs. 10 per share)	435.23	435.23	435.09	435.23	435.09	435.11
11	Other equity						16,395.25
12	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	4.40	0.79	1.31	5.19	2.91	6.18
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	4.39	0.79	1.31	5.18	2.90	6.17

(*not annualised for the quarter and half year)
See accompanying notes to the unaudited standalone financial results

NOTES:

1 The unaudited standalone financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 4 November 2026. The statutory auditors have expressed an unmodified conclusion on these unaudited standalone financial results.

2 The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 "Operating Segments".

3 During the period ended 30 September 2026, the Company has subscribed to the Optionally Convertible Debenture ('OCD') issued by its subsidiaries, detailed as follows:

Name of the entity	Unit number	Date of issuance	Issue price
Saurashtra Medisolutions Private Limited	36,250	9 May 2026	3,300
Sri Parshva Pharma Distributors Private Limited	38,000	27 April 2026	8,400
S.S. Pharma Traders Private Limited	4,000	22 May 2026	55,000
Avenues Pharma Distributors Private Limited	62,500	18 April 2026	5,600

4 Subsequent to the period ended 30 September 2026, the Company has subscribed to 15,00,000 Optionally Convertible Debentures ('OCD') issued by Chhabra Healthcare Solution Private Limited at Rs. 120 per OCD on 03 November 2026.

5 During the period ended 30 September 2026, the Company has allotted 12,135 equity shares of Rs.10 each at a premium of Rs. 794 per share aggregating to Rs. 9.76 million pursuant to exercise of employee stock options.

6 During the period ended 30 September 2026, the Company has granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023.

7 The above unaudited standalone financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 04 November 2026

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Standalone Statement of Assets and Liabilities as at 30 September 2026
(Amount in Millions, unless otherwise stated)

Particulars	30 September 2026 (Unaudited)	31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	170.45	179.15
Right of use assets	182.49	214.15
Other Intangible assets	74.62	81.07
Intangible assets under development	46.99	24.53
Financial assets		
Investments in subsidiaries	8,658.76	7,649.93
Loans	5,342.99	5,726.63
Other financial assets	117.51	84.60
Deferred tax assets (net)	62.22	120.91
Non current tax assets (net)	155.66	201.64
Other non current asset	9.61	4.99
Total non-current assets	**14,821.30**	**14,287.60**
Current assets		
Inventories	583.09	733.34
Financial assets		
Investments	434.44	596.03
Trade receivables	944.53	1,034.66
Cash and cash equivalents	259.43	567.63
Bank balances other than cash and cash equivalent	20.00	15.34
Loans	2,828.66	2,271.95
Other financial assets	2,136.00	1,910.98
Other current assets	269.69	159.09
Total current assets	**7,475.84**	**7,289.02**
TOTAL ASSETS	**22,297.14**	**21,576.62**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	435.23	435.11
Share Application Money Pending Allotment	40.28	-
Other equity	16,649.60	16,395.25
Total equity	**17,125.11**	**16,830.36**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	1,411.30	919.65
Lease liabilities	152.27	188.53
Other financial liabilities	601.48	335.67
Provisions	54.26	83.69
Total non-current liabilities	**2,219.31**	**1,527.54**
Current liabilities		
Financial liabilities		
Borrowings	571.37	157.14
Lease liabilities	69.41	61.75
Trade payables		
i)total outstanding dues of micro enterprises and small enterprises	0.39	0.20
ii)total outstanding dues of creditors other than micro enterprise and small enterprises	830.31	747.72
Other financial liabilities	1,292.33	2,193.47
Other current liabilities	178.60	40.38
Provisions	10.31	18.06
Total current liabilities	**2,952.72**	**3,218.72**
TOTAL LIABILITIES	**5,172.03**	**4,746.26**
TOTAL EQUITY AND LIABILITIES	**22,297.14**	**21,576.62**

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Standalone Statement of cash flows for the period ended 30 September 2026
(Amount in Millions, unless otherwise stated)

Particulars	For the period ended 30 September 2026 (Unaudited)	For the period ended 30 September 2025 (Unaudited)
Cash flow from operating activities		
Profit / (Loss) before tax	289.24	167.74
Adjustments for:		
Depreciation and amortization expenses	62.79	61.45
Finance cost	118.53	13.05
Interest income	(386.05)	(432.85)
Profit on sale of property, plant and equipment	(0.03)	(0.07)
Commission Income on Corporate Guarantee	(33.92)	(19.89)
Gain on termination of lease	-	(3.90)
Provision for expected credit loss	(15.79)	1.43
Fair value gain on mutual funds and derivative instruments	0.37	(7.23)
Net gain on redemption of mutual fund investments	(10.50)	-
Asset written off	-	0.11
Employee stock option expenses	16.63	18.56
	41.27	**(201.60)**
Changes in working capital		
(Increase)/Decrease in inventories	150.25	(163.43)
(Increase)/Decrease in trade receivables	160.50	(228.06)
(Increase)/Decrease in other financial assets	(289.76)	290.91
(Increase)/Decrease in other current assets	(110.60)	1.43
Increase/(Decrease) in trade payables	35.44	66.69
Increase/(Decrease) in other financial liabilities	43.03	(82.54)
Increase/(Decrease) in other current liabilities	138.07	(13.08)
Increase/(Decrease) in provisions and employee benefit	(34.40)	8.55
Cash generated from/(used) in operations	**133.80**	**(321.14)**
Income tax paid (net)	40.86	(60.70)
Net cash flows generated from/(used) in operating activities (A)	**174.66**	**(381.84)**
Cash flow from investing activities		
Purchase consideration paid towards acquisitions of business	(1,866.34)	(651.75)
Proceeds from sale of subsidiary	-	0.20
Loans to related party	(2,159.07)	(1,194.38)
Loan repayment received from related party	1,986.00	799.34
Purchase of Property, Plant and Equipment, including movement in CWIP and capital advances	(43.02)	(75.23)
Proceeds from sale of property, plant and equipment	-	1.04
Commission income on corporate guarantee	33.92	19.89
Proceeds/(investment) in mutual funds (net)	171.72	106.35
(Increase) / Decrease in fixed deposits with bank having maturity more than three months (net)	(27.21)	38.48
Interest received	626.66	430.90
Net cash flow generated from/(used) in investing activities (B)	**(1,277.34)**	**(525.15)**
Cash flow from financing activities		
Proceeds from issue of equity shares on exercise of ESOP	9.76	0.96
Receipt of share Application Money	40.28	1.63
Proceeds from term loan	900.00	-
Payment of lease liabilities	(39.94)	(52.66)
Interest paid	(108.39)	(0.06)
Net cash generated from/(used in) in financing activities (C)	**801.71**	**(50.13)**
Net increase/ (decrease) in cash and cash equivalents (A+B+C)	**(300.97)**	**(957.12)**
Cash and cash equivalents at the beginning of the period*	560.40	1,511.80
Cash and cash equivalents at the end of the period	**259.43**	**554.68**

*Restated Pursuant to amendment to Ind AS 109

NOTES:

1 The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard (Ind AS) 7, Statement of Cash Flows as specified in the Companies (Indian Accounting Standards), Rules, 2015 (as amended).

2 Cash and cash equivalents comprise:

Particulars	For the period ended 30 September 2026 (Unaudited)	For the period ended 30 September 2025 (Unaudited)
Balances with banks		
On current accounts	259.21	301.74
Fixed deposits with maturity of less than 3 months	-	252.64
Cash on hand	0.22	0.30
Total cash and cash equivalents at end of the year	**259.43**	**554.68**

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on Standalone unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to-date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Entero Healthcare Solutions Limited (hereinafter referred to as 'the Company'), for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

VIRENDRA ZAVERBHAI KANAK

Digitally signed by VIRENDRA ZAVERBHAI KANAK
Date: 2026.11.04 18:11:52 +05'30'

Virendra Kanak
Partner
Membership No.: 110811
UDIN: 26110811CKNERO3905
Place: Mumbai
Date: November 04, 2026

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Statement of unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2026

(Rs. in Million, except per equity share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
1	**Income**						
	a) Revenue from operations	20,870.75	19,404.95	15,709.48	40,275.70	29,747.67	65,912.12
	b) Other income	39.92	30.07	47.91	69.99	106.16	192.37
	Total Income	**20,910.67**	**19,435.02**	**15,757.39**	**40,345.69**	**29,853.83**	**66,104.49**
2	**Expenses**						
	a) Purchase of Stock-in-trade	18,662.84	17,253.16	13,983.28	35,916.00	26,973.44	59,148.38
	b) Changes in inventories of Stock-in-trade	(191.87)	(61.81)	118.22	(253.68)	(229.46)	(40.08)
	c) Employee benefits expense	707.21	694.16	592.06	1,401.37	1,167.63	2,454.99
	d) Finance costs	231.38	205.72	123.98	437.10	230.62	543.85
	e) Depreciation and amortisation expense	131.29	123.05	98.34	254.34	187.03	432.93
	f) Other expenses	585.95	549.54	395.26	1,135.49	714.69	1,689.28
	Total Expenses	**20,126.80**	**18,763.82**	**15,311.14**	**38,890.62**	**29,043.95**	**64,229.35**
3	**Profit before exceptional items and tax (1) - (2)**	**783.87**	**671.20**	**446.25**	**1,455.07**	**809.88**	**1,875.14**
4	**Exceptional Items**	-	-	-	-	-	81.78
5	**Profit before tax (3) - (4)**	**783.87**	**671.20**	**446.25**	**1,455.07**	**809.88**	**1,793.35**
6	**Tax expenses**						
	Current tax (including tax expense of earlier year)	132.56	176.54	126.62	309.10	207.71	594.80
	Deferred tax charge/(credit)	43.89	(25.85)	(46.37)	18.04	(66.15)	(259.84)
	Total tax expenses	**176.45**	**150.69**	**80.25**	**327.14**	**141.56**	**334.96**
7	**Profit for the period/year (5) – (6)**	**607.42**	**520.51**	**366.00**	**1,127.93**	**668.32**	**1,458.39**
8	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss						
	Remeasurement (losses)/gains on defined benefit plan	27.58	(1.74)	(5.62)	25.84	(3.98)	(7.86)
	Income tax effect on above	(6.97)	0.44	1.47	(6.53)	1.05	1.95
	Total other comprehensive income	**20.61**	**(1.30)**	**(4.15)**	**19.31**	**(2.93)**	**(5.91)**
9	**Total comprehensive income (7) + (8)**	**628.03**	**519.21**	**361.85**	**1,147.24**	**665.39**	**1,452.48**
10	**Profit attributable to:**						
	Owners of the Company	455.43	381.62	316.01	837.05	594.00	1,150.42
	Non-controlling interests	151.99	138.89	49.99	290.88	74.32	307.98
11	**Other comprehensive income attributable to:**						
	Owners of the Company	18.51	(1.28)	(3.75)	17.23	(2.82)	(5.82)
	Non-controlling interests	2.10	(0.02)	(0.40)	2.08	(0.11)	(0.09)
12	**Total comprehensive income attributable to:**						
	Owners of the Company	473.94	380.34	312.26	854.28	591.18	1,144.60
	Non-controlling interests	154.09	138.87	49.59	292.96	74.21	307.89
13	Paid-up equity share capital (face value - Rs. 10 per share)	435.23	435.23	435.09	435.23	435.09	435.11
14	Other equity						16,450.99
15	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	10.47	8.77	7.26	19.24	13.65	26.44
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	10.45	8.76	7.25	19.20	13.63	26.40

(*not annualised for the quarter and half year)
See accompanying notes to the unaudited consolidated financial results

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

NOTES:

1 The unaudited consolidated financial results are prepared in accordance with the recognition and measurement principles provided in Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', the provisions of the Companies Act, 2013 (the Act), and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016, as amended. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited consolidated financial results of Entero Healthcare Solutions Limited ("the Holding Company" or "the Company"), and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 4 November 2026. The statutory auditors have expressed an unmodified conclusion on these unaudited consolidated financial results.

2 The Group operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Group has only one reportable segment as per Ind AS 108 "Operating Segments".

3 During the year ended 31 March 2026, the Holding Company has entered into share purchase agreement with following entities, resulting these entities became the subsidiaries of Company. The Holding Company has accounted these acquisitions as per Ind AS 103- 'Business Combinations', on provisional basis in the audited consolidated financial results. The figures for the quarter and half year ended 30 September 2026 include figures of the aforesaid acquired entities from the date of share transfer as mentioned below, and are not comparable with the corresponding/ comparative period:

Name of the entity	Date of share transfer	Number of Equity Shares Acquired	% of shareholding
Ramson Medical Distributors Private Limited	30 June 2025	7,00,000	70%
Sai RK Pharma Private Limited	19 July 2025	7,000	70%
Well Wisher Pharma Private Limited	05 September 2025	7,000	70%
Anand Medilink Private Limited	01 October 2025	8,000	80%
Ace Cardiopathy Solutions Private Limited	06 October 2025	1,78,840	60%
Bioaide Technologies Private Limited	26 November 2025	76,032	80%
Anand Chemiceutics Private Limited	07 February 2026	51,510	51.51%

4 During the period ended 30 September 2026, the Company has allotted 12,135 equity shares of Rs.10 each at a premium of Rs. 794 per share aggregating to Rs. 9.76 million pursuant to exercise of employee stock options.

5 During the period ended 30 September 2026, R S M Pharma Private Limited (Wholly owned Subsidiary of the Company) has subscribed to 100% equity shares of Qurovia Lifesciences Private Limited on 25 July 2026, resulting this entity become step down subsidiary of the Company.

6 During the Period ended 30 September 2026, the Company has granted 24,800 employee stock options under Entero Employee Stock Option Plan 2023.

7 Subsequent to period ended 30 September 2026, Sai Pharma Distributors Private Limited (Subsidiary of the Company) has entered into business transfer agreement with Vishal Surgicals and Vishal Surgicals & Medicals for the acquisition of 100% business undertaking on slump sale basis on 12 October 2026.

8 The above unaudited consolidated financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 04 November 2026

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Consolidated Statement of Assets and Liabilities as at 30 September 2026
(Amount in million, unless otherwise stated)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,145.14	1,031.11
Right of use asset	960.26	972.99
Goodwill	7,490.90	7,490.90
Other intangible assets	80.03	85.32
Intangible asset under development	46.99	24.53
Financial assets		
Other financial assets	506.46	493.23
Deferred tax asset (net)	516.39	540.28
Non Current tax assets (net)	225.44	269.40
Other non-current assets	12.40	10.51
Total non-current assets	**10,984.01**	**10,918.27**
Current assets		
Inventories	8,670.45	8,416.77
Financial assets		
Investments	1,269.49	1,298.86
Trade receivables	14,608.85	12,124.42
Cash and cash equivalents	961.38	1,468.76
Bank balances other than cash and cash equivalents	72.24	149.13
Other financial assets	509.87	307.60
Other current assets	1,634.95	1,265.77
Non-current Assets Held for Sale	-	53.05
Total current assets	**27,727.23**	**25,084.36**
TOTAL ASSETS	**38,711.24**	**36,002.63**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	435.23	435.11
Share Application Money Pending Allotment	40.28	-
Other equity	17,335.61	16,450.99
Equity attributable to owners of the Company	**17,811.12**	**16,886.10**
Non-Controlling Interests	932.31	639.36
Total equity	**18,743.43**	**17,525.46**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	1,881.65	1,225.60
Lease Liabilities	759.83	823.79
Other financial liabilities	601.48	335.67
Provisions	195.11	216.00
Deferred tax Liabilities (net)	1.09	0.41
Total non-current liabilities	**3,439.16**	**2,601.47**
Current liabilities		
Financial liabilities		
Borrowings	6,057.17	4,441.23
Lease Liabilities	336.48	280.90
Trade payables		
i) total outstanding dues of micro enterprises and small enterprises	870.21	428.83
ii) total outstanding dues of creditors other than micro enterprise and small enterprise	6,917.25	6,824.45
Other financial liabilities	1,882.02	3,596.52
Other current liabilities	240.27	97.02
Provisions	32.67	51.02
Current tax liabilities (net)	192.58	155.73
Total current liabilities	**16,528.65**	**15,875.70**
TOTAL LIABILITIES	**19,967.81**	**18,477.17**
TOTAL EQUITY AND LIABILITIES	**38,711.24**	**36,002.63**

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

Entero Healthcare Solutions Limited
Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003
Corporate Office: Entero House, Crystal Plaza - 158, C.S.T. Road, Kalina, Mumbai-400 098, Maharashtra
CIN:L74999HR2018PLC072204
Tel. No.: 022-26529100
Email: info@enterohealthcare.com
Website: www.enterohealthcare.com

Consolidated Statement of Cash Flows for the period ended 30 September 2026
(Amount in million, unless otherwise stated)

Particulars	For the Period ended 30 September 2026 (Unaudited)	For the Period ended 30 September 2025 (Unaudited)
Cash flow from operating activities		
Profit before tax	1,455.07	809.88
Adjustments for:		
Depreciation and amortization expense	254.34	187.03
Finance costs	437.10	230.62
Provision for expected credit loss on trade receivables	56.38	31.08
Provision for claim receivable	60.05	-
(Profit)/Loss on sale of property, plant and equipment (net)	(0.01)	0.01
Interest income	(12.21)	(80.62)
Net gain on redemption of mutual fund investments	(18.39)	(8.06)
Fair value gain on mutual funds and derivative instruments	(22.10)	(9.44)
Gain on modification / termination of lease	(3.98)	(4.23)
Interest income on income tax refund	(8.41)	(0.00)
Employee stock option expenses	16.63	18.56
	2,214.47	**1,174.84**
Changes in working capital		
(Increase) / Decrease in inventories	(253.68)	(254.51)
(Increase) / Decrease in loans	-	2.77
(Increase) / Decrease in trade receivables	(2,356.04)	(1,150.69)
(Increase) / Decrease in other financial assets	97.60	(93.07)
(Increase) / Decrease in other current assets	(384.32)	47.47
Increase / (Decrease) in trade payables	286.26	151.05
Increase / (Decrease) in other current liabilities	143.25	(11.10)
Increase / (Decrease) in other financial liabilities	38.10	(201.80)
Increase / (Decrease) in provisions and employee benefits	(21.49)	20.94
Cash generated/(used) in operations	**(235.85)**	**(314.10)**
Income tax paid (net)	(229.54)	(258.62)
Net cash flow generated from/ (used in) operating activities (A)	**(465.39)**	**(572.73)**
Cash flow from investing activities		
Purchase consideration paid towards acquisitions of business	(1,662.75)	(795.11)
Purchase of property, plant and equipment, intangible including movement in CWIP and capital advances	(225.35)	(106.23)
Proceed / (Investment) in mutual funds (net)	64.34	(72.04)
Proceeds from sale of property, plant and equipment	3.39	1.52
Interest received	15.38	73.62
(Increase) / Decrease in fixed deposits with bank having maturity more than three months (net)	5.24	349.17
Net cash generated from/(used in) investing activities (B)	**(1,799.75)**	**(549.08)**
Cash flow from financing activities		
Proceeds from issue of equity shares on exercise of ESOP	9.77	0.96
Receipt of share Application Money	40.28	1.63
Proceeds from long term loan	1,116.27	(11.61)
Repayment of long term loan	(139.10)	-
Proceeds/(Repayment) of short-term borrowings (net)	1,311.14	(34.25)
Payment of lease liabilities	(207.39)	(173.55)
Finance costs paid	(375.42)	(176.30)
Net cash generated from/(used in) financing activities (C)	**1,755.55**	**(393.12)**
Net increase/(decrease) in cash and cash equivalents (A+B+C)	**(509.59)**	**(1,514.93)**
Cash and cash equivalents at the beginning of the period*	1,470.97	2,292.78
Add : on acquisition of business	-	1.75
Less : on Disinvestment of business	-	(22.56)
Cash and cash equivalents at the end of the period	**961.38**	**757.04**

*Restated persuant to amendment to Ind AS 109

NOTES:

1 The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard (Ind AS) 7, Statement of Cash Flows as specified in the Companies (Indian Accounting Standards), Rules, 2015 (as amended).

2 Cash and cash equivalents comprise of:

Particulars	As at 30 September 2026 (Unaudited)	As at 30 September 2025 (Unaudited)
Balances with banks		
On current accounts	849.56	706.75
Fixed deposits with maturity of less than 3 months	21.77	-
Cash on hand	90.05	50.29
Total cash and cash equivalents at end of the period	**961.38**	**757.04**

Entero Healthcare Solutions Limited

MSKA & ASSOCIATES LLP Chartered Accountants

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

HO
602, Floor 6, Raheja Titanium
Western Express Highway, Geetanjali
Railway Colony, Ram Nagar, Goregaon (E)
Mumbai 400063, INDIA
Tel: +91 22 6974 0200

Independent Auditor's Review Report on consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to-date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Entero Healthcare Solutions Limited (hereinafter referred to as 'the Holding Company') which includes its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 30, 2026 and the year to-date results for the period from April 01, 2026 to September 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the entities listed in Annexure A.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of 5 subsidiaries included in the Statement, whose interim financial information reflects total assets of Rs. 9,210.06 million as at September 30, 2026 and total revenues of Rs. 4,289.01 million and Rs. 8,046.76 million, total net profit after tax of Rs. 253.93 million and Rs. 473.87 million and total comprehensive income of Rs. 254.35 million and Rs. 474.27 million, for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, and cash flows (net) of Rs. 0.23 million for the period from April 01, 2026 to September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

7. The Statement includes the interim financial information of 22 subsidiaries which have not been reviewed by their auditors and are not subject to review, whose interim financial information reflects total assets of Rs. 6,815.83 million as at September 30, 2026 and total revenue of Rs. 3,629.13 million and Rs. 7,152.23 million, total net profit after tax of Rs. 78.88 million and Rs. 133.49 million and total comprehensive income of Rs. 79.91 million and Rs. 134.40 million for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, and cash flows (net) of Rs. (80.05) million for the period from April 01, 2026 to September 30, 2026, as considered in the Statement. These interim financial information have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

VIRENDRA ZAVERBHAI KANAK

Digitally signed by VIRENDRA ZAVERBHAI KANAK
Date: 2026.11.04 18:14:44 +05'30'

Virendra Kanak
Partner
Membership No.: 110811
UDIN: 26110811CPWKLT4294

Place: Mumbai
Date: November 04, 2026

Annexure A to the Independent Auditor's Review Report on Consolidated unaudited financial results of Entero Healthcare Solutions Limited for the quarter and year to-date pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Sr. No	Name of the entity	Relationship with Holding Company
1	Novacare Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
2	R S M Pharma Private Limited	Wholly owned Subsidiary Company
3	Avenues Pharma Distributors Private Limited	Wholly owned Subsidiary Company
4	Chirag Medicare Solutions Private Limited	Wholly owned Subsidiary Company
5	Chethana Pharma Private Limited	Wholly owned Subsidiary Company
6	Jaggi Enterprises Private Limited	Wholly owned Subsidiary Company
7	Vasavi Medicare Solutions Private Limited	Wholly owned Subsidiary Company
8	SVMED Solutions Private Limited	Wholly owned Subsidiary Company
9	Millennium Medisolutions Private Limited	Wholly owned Subsidiary Company
10	G.S. Pharmaceutical Distributors Private Limited	Wholly owned Subsidiary Company
11	Getwell Medicare Solution Private Limited	Wholly owned Subsidiary Company
12	Galaxystar Pharma Distributors Private Limited	Wholly owned Subsidiary Company
13	Barros Enterprises Private Limited	Wholly owned Subsidiary Company
14	Sesha Balajee Medisolutions Private Limited	Wholly owned Subsidiary Company
15	Rada Medisolutions Private Limited	Wholly owned Subsidiary Company
16	Sri Parshva Pharma Distributors Private Limited	Wholly owned Subsidiary Company
17	Sri Rama Pharmaceutical Distributors Private Limited	Wholly owned Subsidiary Company
18	Western Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
19	Chhabra Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
20	Chethana Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
21	S.S. Pharma Traders Private Limited	Wholly owned Subsidiary Company
22	Sundarlal Pharma Distributors Private Limited	Wholly owned Subsidiary Company
23	New Siva Agencies Private Limited	Wholly owned Subsidiary Company
24	Saurashtra Medisolutions Private Limited	Wholly owned Subsidiary Company
25	New RRPD Private Limited	Wholly owned Subsidiary Company
26	Sree Venkateshwara Medisolutions Private Limited	Wholly owned Subsidiary Company
27	SVS Lifesciences Private Limited	Wholly owned Subsidiary Company
28	Swami Medisolutions Private Limited	Wholly owned Subsidiary Company
29	Atreja Healthcare Solutions Private Limited	Wholly owned Subsidiary Company
30	Calcutta Medisolutions Private Limited	Wholly owned Subsidiary Company
31	City Pharma Distributors Private Limited	Wholly owned Subsidiary Company
32	Curever Pharma Private Limited	Wholly owned Subsidiary Company
33	Entero R.S Enterprises Private Limited	Wholly owned Subsidiary Company
34	Dhanvanthri Super Speciality Private Limited	Subsidiary Company
35	Avenir Lifecare Pharma Private Limited	Subsidiary Company
36	Devi Pharma Wellness Private Limited	Wholly owned Subsidiary Company

Sr. No	Name of the entity	Relationship with Holding Company
37	Gourav Medical Agencies Private Limited	Subsidiary Company
38	Srinivasa Lifecare Private Limited	Subsidiary Company
39	Sai Pharma Distributor Private Limited	Subsidiary Company
40	Peerless Biotech Private Limited	Subsidiary Company
41	Ujjain Maheshwari Pharma Distributor Private Limited	Wholly owned Subsidiary Company
42	Ramson Medical Distributors Private Limited	Subsidiary Company
43	Sai RK Pharma Private Limited	Subsidiary Company
44	Well Wisher Pharma Private Limited	Subsidiary Company
45	Anand Medilink Private Limited	Subsidiary Company
46	Ace Cardiopathy Solutions Private Limited	Subsidiary Company
47	Bioaide Technologies Private Limited	Subsidiary Company
48	Anand Chemiceutics Private Limited	Subsidiary Company
49	Qurovia Lifesciences Private Limited (w.e.f July 25, 2026)	Step Down Subsidiary Company